中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2014年
6期
13-15
,共3页
樊锐太%刘云%王鑫%孙银银%吴竞
樊銳太%劉雲%王鑫%孫銀銀%吳競
번예태%류운%왕흠%손은은%오경
食管癌%恩度%同步放化疗%血管内皮生长因子
食管癌%恩度%同步放化療%血管內皮生長因子
식관암%은도%동보방화료%혈관내피생장인자
Esophageal carcinoma%Endostar%Concurrent chemoradiotherapy%Serum vascular endothelial growth factor
目的 探讨恩度联合放化疗治疗局部中晚期食管癌患者的近期疗效.方法 将55例患者随机分为实验组28例和对照组27例,两组均采用三维适形放疗60 ～66 Gy和5-FU/DDP化疗,实验组从放疗起每天接受恩度静脉滴注7.5 mg/m2,第1 ～14天,连用2个周期.治疗结束后比较两组有效率、无进展生存期、生存率及不良反应,同时检测治疗前后血清血管内皮生长因子(VEGF)浓度.结果 实验组和对照组有效率为89.0％和74.1％(P =0.226);1、2、3年总生存率分别为71.9％、50.0％、34.3％和52.0％、33.3％、20.0％ (P =0.046);无进展生存期为15个月和8个月(P=0.015).无明显恩度相关的不良反应.两组血清VEGF水平治疗后比较差异有统计学意义(P =0.009).结论 恩度联合放化疗治疗食管癌疗效显著,能同时降低血清VEGF水平,且耐受性良好.
目的 探討恩度聯閤放化療治療跼部中晚期食管癌患者的近期療效.方法 將55例患者隨機分為實驗組28例和對照組27例,兩組均採用三維適形放療60 ～66 Gy和5-FU/DDP化療,實驗組從放療起每天接受恩度靜脈滴註7.5 mg/m2,第1 ～14天,連用2箇週期.治療結束後比較兩組有效率、無進展生存期、生存率及不良反應,同時檢測治療前後血清血管內皮生長因子(VEGF)濃度.結果 實驗組和對照組有效率為89.0％和74.1％(P =0.226);1、2、3年總生存率分彆為71.9％、50.0％、34.3％和52.0％、33.3％、20.0％ (P =0.046);無進展生存期為15箇月和8箇月(P=0.015).無明顯恩度相關的不良反應.兩組血清VEGF水平治療後比較差異有統計學意義(P =0.009).結論 恩度聯閤放化療治療食管癌療效顯著,能同時降低血清VEGF水平,且耐受性良好.
목적 탐토은도연합방화료치료국부중만기식관암환자적근기료효.방법 장55례환자수궤분위실험조28례화대조조27례,량조균채용삼유괄형방료60 ～66 Gy화5-FU/DDP화료,실험조종방료기매천접수은도정맥적주7.5 mg/m2,제1 ～14천,련용2개주기.치료결속후비교량조유효솔、무진전생존기、생존솔급불량반응,동시검측치료전후혈청혈관내피생장인자(VEGF)농도.결과 실험조화대조조유효솔위89.0％화74.1％(P =0.226);1、2、3년총생존솔분별위71.9％、50.0％、34.3％화52.0％、33.3％、20.0％ (P =0.046);무진전생존기위15개월화8개월(P=0.015).무명현은도상관적불량반응.량조혈청VEGF수평치료후비교차이유통계학의의(P =0.009).결론 은도연합방화료치료식관암료효현저,능동시강저혈청VEGF수평,차내수성량호.
Objective To investigate the short-term effect of recombinant human endostatin (Endostar) combined with chemoradiotherapy(CRT) on patients with locally advanced esophageal squamous cell carcinoma(ESCC).Methods Twenty-eight patients were treated with Endostar plus CRT(group E)and 27 patients were treated with CRT(group C).All the patients received three-dimensional conformal radiotherapy of 60-66 Gy and concurrent chemotherapy of 5 fluorouracil and cisplatin.Endostar was administered at a dose level of 7.5 mg/(m2 · d) on the day of CRT(d 1-14)and 2 cycles were given.The response rate (RR),progression free survival(PFS),overall survival rate(OS) and side effects were assessed after treatment.The serum VEGF(S-VEGF) levels were measured before and after the treatment in both groups.Results The RR in group E was 89.0％ and 74.1％ in group C(P =0.226).The 1,2,3OS rate was 71.9％,50.0％,34.3％ and 52.0％,33.3％,20.0％ (P =0.046),PFS were 15 months and 8 months for group E and group C respectively(P =0.0015).There were no side effects associated with Endostar.There were significant differences in S-VEGF level after treatment (P =0.009) between the two groups.Conclusions The effect of Endostar combined with chemoradiotherapy on patients with locally advanced esophageal squamous cell carcinoma is remarkable,it can reduce the S-VEGF level,and has good tolerance.
